;PMID: 7885185
;source_file_2879.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:38..148] = [t:38..148]
;2)section:[e:152..203] = [t:152..203]
;3)section:[e:207..296] = [t:207..296]
;4)sentence:[e:300..496] = [t:300..496]
;5)sentence:[e:497..692] = [t:497..692]
;6)sentence:[e:694..825] = [t:694..825]
;7)sentence:[e:826..1027] = [t:826..1027]
;8)sentence:[e:1028..1173] = [t:1028..1173]
;9)sentence:[e:1174..1359] = [t:1174..1359]
;10)section:[e:1363..1407] = [t:1363..1407]

;section 0 Span:0..32
;Life Sci.  1995;56(10):PL219-24.
(SEC
  (FRAG (NNP:[0..4] Life) (NNP:[5..8] Sci) (.:[8..9] .) (CD:[11..15] 1995)
        (::[15..16] ;) (CD:[16..18] 56) (-LRB-:[18..19] -LRB-) (CD:[19..21] 10)
        (-RRB-:[21..22] -RRB-) (::[22..23] :) (NN:[23..31] PL219-24)
        (.:[31..32] .)))

;sentence 1 Span:38..148
;Inhibition of plasma membrane Ca(2+)-ATPase pump activity in cultured C6
;glioma  cells by halothane and xenon.
;[52..81]:gene-protein:"plasma membrane Ca(2+)-ATPase"
;[108..124]:malignancy-type:"C6 glioma  cells"
(SENT
  (NP-HLN
    (NP (NN:[38..48] Inhibition))
    (PP (IN:[49..51] of)
      (NP
        (NML
          (NML
            (NML (NN:[52..58] plasma) (NN:[59..67] membrane))
            (NN:[68..81] Ca-LRB-2+-RRB--ATPase))
          (NN:[82..86] pump))
        (NN:[87..95] activity)))
    (PP-LOC (IN:[96..98] in)
      (NP (VBN:[99..107] cultured)
         (NN:[108..110] C6) (NN:[111..117] glioma) (NNS:[119..124] cells)))
    (PP (IN:[125..127] by)
      (NP (NN:[128..137] halothane) (CC:[138..141] and) (NN:[142..147] xenon)))
    (.:[147..148] .)))

;section 2 Span:152..203
;Singh G, Janicki PK, Horn JL, Janson VE, Franks JJ.
(SEC
  (FRAG (NNP:[152..157] Singh) (NNP:[158..159] G) (,:[159..160] ,)
        (NNP:[161..168] Janicki) (NNP:[169..171] PK) (,:[171..172] ,)
        (NNP:[173..177] Horn) (NNP:[178..180] JL) (,:[180..181] ,)
        (NNP:[182..188] Janson) (NNP:[189..191] VE) (,:[191..192] ,)
        (NNP:[193..199] Franks) (NNP:[200..203] JJ.)))

;section 3 Span:207..296
;Department of Anesthesiology, Vanderbilt University Medical Center,
;Nashville,  TN 37232.
(SEC
  (FRAG (NNP:[207..217] Department) (IN:[218..220] of)
        (NNP:[221..235] Anesthesiology) (,:[235..236] ,)
        (NNP:[237..247] Vanderbilt) (NNP:[248..258] University)
        (NNP:[259..266] Medical) (NNP:[267..273] Center) (,:[273..274] ,)
        (NNP:[275..284] Nashville) (,:[284..285] ,) (NN:[287..289] TN)
        (CD:[290..295] 37232) (.:[295..296] .)))

;sentence 4 Span:300..496
;We have compared the effect of two inhalational anesthetics, halothane and 
;xenon, on Ca(2+)-ATPase (PMCA) pumping activity in plasma membrane vesicles 
;prepared from cultured rat C6 glioma cells.
;[386..399]:gene-protein:"Ca(2+)-ATPase"
;[401..405]:gene-protein:"PMCA"
;[480..495]:malignancy-type:"C6 glioma cells"
(SENT
  (S
    (NP-SBJ (PRP:[300..302] We))
    (VP (VBP:[303..307] have)
      (VP (VBN:[308..316] compared)
        (NP
          (NP (DT:[317..320] the) (NN:[321..327] effect))
          (PP (IN:[328..330] of)
            (NP
              (NP (CD:[331..334] two) (JJ:[335..347] inhalational)
                  (NNS:[348..359] anesthetics))
              (,:[359..360] ,)
              (NP (NN:[361..370] halothane) (CC:[371..374] and)
                  (NN:[376..381] xenon))))
          (,:[381..382] ,)
          (PP (IN:[383..385] on)
            (NP
              (NML
                (NML (NN:[386..399] Ca-LRB-2+-RRB--ATPase))
                (NML (-LRB-:[400..401] -LRB-) (NN:[401..405] PMCA)
                     (-RRB-:[405..406] -RRB-)))
              (NN:[407..414] pumping) (NN:[415..423] activity))))
        (PP-LOC (IN:[424..426] in)
          (NP
            (NP (NN:[427..433] plasma) (NN:[434..442] membrane)
                (NNS:[443..451] vesicles))
            (VP (VBN:[453..461] prepared)
              (NP (-NONE-:[461..461] *))
              (PP (IN:[462..466] from)
                (NP (VBN:[467..475] cultured) (NN:[476..479] rat)
                   (NN:[480..482] C6) (NN:[483..489] glioma)
                   (NNS:[490..495] cells))))))))
    (.:[495..496] .)))

;sentence 5 Span:497..692
;Halothane, at concentrations ranging  from 0.5 to 1.75 vol% (equivalent to
;0.5 to 1.6 MAC), significantly inhibited  Ca2+ uptake (transport) by plasma
;membrane vesicles in a dose-related fashion.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[497..506] Halothane))
      (,:[506..507] ,)
      (PP (IN:[508..510] at)
        (NP
          (NP (NNS:[511..525] concentrations))
          (VP (VBG:[526..533] ranging)
            (PP
              (PP (IN:[535..539] from)
                (NP (CD:[540..543] 0.5)
                  (NML-1 (-NONE-:[543..543] *RNR*))))
              (PP (TO:[544..546] to)
                (NP (CD:[547..551] 1.75)
                  (NML-1 (-NONE-:[551..551] *RNR*))))
              (NML-1 (NN:[552..555] vol) (NN:[555..556] %))
              (PRN (-LRB-:[557..558] -LRB-)
                (ADJP (JJ:[558..568] equivalent)
                  (PP (TO:[569..571] to)
                    (NP
                      (QP (CD:[572..575] 0.5) (TO:[576..578] to)
                          (CD:[579..582] 1.6))
                      (NN:[583..586] MAC))))
                (-RRB-:[586..587] -RRB-)))))))
    (,:[587..588] ,)
    (ADVP (RB:[589..602] significantly))
    (VP (VBD:[603..612] inhibited)
      (NP
        (NP (NN:[614..618] Ca2+) (NN:[619..625] uptake))
        (PRN (-LRB-:[626..627] -LRB-)
          (NP (NN:[627..636] transport))
          (-RRB-:[636..637] -RRB-))
        (PP (IN:[638..640] by)
          (NP
            (NML (NN:[641..647] plasma) (NN:[648..656] membrane))
            (NNS:[657..665] vesicles))))
      (PP (IN:[666..668] in)
        (NP (DT:[669..670] a)
          (ADJP (NN:[671..675] dose) (HYPH:[675..676] -)
                (VBN:[676..683] related))
          (NN:[684..691] fashion))))
    (.:[691..692] .)))

;sentence 6 Span:694..825
;Xenon, at partial pressures ranging from 0.5 to 1.5 atm (equivalent to 0.5 to
; 1.6 MAC), similarly inhibited PMCA pumping activity.
;[803..807]:gene-protein:"PMCA"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[694..699] Xenon))
      (,:[699..700] ,)
      (PP (IN:[701..703] at)
        (NP
          (NP (JJ:[704..711] partial) (NNS:[712..721] pressures))
          (VP (VBG:[722..729] ranging)
            (PP
              (PP (IN:[730..734] from)
                (NP (CD:[735..738] 0.5)
                  (NML-1 (-NONE-:[738..738] *RNR*))))
              (PP (TO:[739..741] to)
                (NP (CD:[742..745] 1.5)
                  (NML-1 (-NONE-:[745..745] *RNR*))))
              (NML-1 (NN:[746..749] atm))
              (PRN (-LRB-:[750..751] -LRB-)
                (ADJP (JJ:[751..761] equivalent)
                  (PP (TO:[762..764] to)
                    (NP
                      (QP (CD:[765..768] 0.5) (TO:[769..771] to)
                          (CD:[773..776] 1.6))
                      (NN:[777..780] MAC))))
                (-RRB-:[780..781] -RRB-)))))))
    (,:[781..782] ,)
    (ADVP (RB:[783..792] similarly))
    (VP (VBD:[793..802] inhibited)
      (NP
        (NML (NN:[803..807] PMCA) (NN:[808..815] pumping))
        (NN:[816..824] activity)))
    (.:[824..825] .)))

;sentence 7 Span:826..1027
;Additive effects on  suppression of PMCA pump activity were observed when C6
;cell plasma membrane  vesicles were exposed to increasing partial pressures
;of xenon in the presence  of halothane (1 vol%).
;[862..866]:gene-protein:"PMCA"
;[900..907]:malignancy-type:"C6 cell"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[826..834] Additive) (NNS:[835..842] effects))
      (PP (IN:[843..845] on)
        (NP
          (NP (NN:[847..858] suppression))
          (PP (IN:[859..861] of)
            (NP
              (NML (NN:[862..866] PMCA) (NN:[867..871] pump))
              (NN:[872..880] activity))))))
    (VP (VBD:[881..885] were)
      (VP (VBN:[886..894] observed)
        (NP-1 (-NONE-:[894..894] *))
        (SBAR
          (WHADVP-3 (WRB:[895..899] when))
          (S
            (NP-SBJ-2
              (NML (NN:[900..902] C6) (NN:[903..907] cell))
              (NML (NN:[908..914] plasma) (NN:[915..923] membrane))
              (NNS:[925..933] vesicles))
            (VP (VBD:[934..938] were)
              (VP (VBN:[939..946] exposed)
                (NP-2 (-NONE-:[946..946] *))
                (PP-CLR (TO:[947..949] to)
                  (NP
                    (NP (VBG:[950..960] increasing) (JJ:[961..968] partial)
                        (NNS:[969..978] pressures))
                    (PP (IN:[979..981] of)
                      (NP (NN:[982..987] xenon)))))
                (PP (IN:[988..990] in)
                  (NP
                    (NP (DT:[991..994] the) (NN:[995..1003] presence))
                    (PP (IN:[1005..1007] of)
                      (NP (NN:[1008..1017] halothane)))
                    (PRN (-LRB-:[1018..1019] -LRB-)
                      (NP (CD:[1019..1020] 1) (NN:[1021..1024] vol)
                          (NN:[1024..1025] %))
                      (-RRB-:[1025..1026] -RRB-))))
                (ADVP-TMP-3 (-NONE-:[1026..1026] *T*))))))))
    (.:[1026..1027] .)))

;sentence 8 Span:1028..1173
;Halothane also inhibited PMCA pumping in cells from two  other lines of
;neural origin, B104 (rat neuroblastoma) and PC12 (rat  pheochromocytoma).
;[1053..1057]:gene-protein:"PMCA"
;[1125..1138]:malignancy-type:"neuroblastoma"
;[1155..1171]:malignancy-type:"pheochromocytoma"
(SENT
  (S
    (NP-SBJ (NN:[1028..1037] Halothane))
    (ADVP (RB:[1038..1042] also))
    (VP (VBD:[1043..1052] inhibited)
      (NP (NN:[1053..1057] PMCA) (NN:[1058..1065] pumping))
      (PP-LOC (IN:[1066..1068] in)
        (NP
          (NP (NNS:[1069..1074] cells))
          (PP (IN:[1075..1079] from)
            (NP
              (NP
                (NP (CD:[1080..1083] two) (JJ:[1085..1090] other)
                    (NNS:[1091..1096] lines))
                (PP (IN:[1097..1099] of)
                  (NP (JJ:[1100..1106] neural) (NN:[1107..1113] origin))))
              (,:[1113..1114] ,)
              (NP
                (NP (NN:[1115..1119] B104)
                  (PRN (-LRB-:[1120..1121] -LRB-)
                    (NP (NN:[1121..1124] rat) (NN:[1125..1138] neuroblastoma))
                    (-RRB-:[1138..1139] -RRB-)))
                (CC:[1140..1143] and)
                (NP (NN:[1144..1148] PC12)
                  (PRN (-LRB-:[1149..1150] -LRB-)
                    (NP (NN:[1150..1153] rat) (NN:[1155..1171] pheochromocytoma))
                    (-RRB-:[1171..1172] -RRB-)))))))))
    (.:[1172..1173] .)))

;sentence 9 Span:1174..1359
;Studies described in this report support the thesis that PMCA  in cells of
;neural origin is inhibited by quite different inhalational  anesthetics at
;clinically relevant concentrations.
;[1231..1235]:gene-protein:"PMCA"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1174..1181] Studies))
      (VP (VBN:[1182..1191] described)
        (NP (-NONE-:[1191..1191] *))
        (PP (IN:[1192..1194] in)
          (NP (DT:[1195..1199] this) (NN:[1200..1206] report)))))
    (VP (VBP:[1207..1214] support)
      (NP
        (NP (DT:[1215..1218] the) (NN:[1219..1225] thesis))
        (SBAR (IN:[1226..1230] that)
          (S
            (NP-SBJ-1
              (NP (NN:[1231..1235] PMCA))
              (PP-LOC (IN:[1237..1239] in)
                (NP
                  (NP (NNS:[1240..1245] cells))
                  (PP (IN:[1246..1248] of)
                    (NP (JJ:[1249..1255] neural) (NN:[1256..1262] origin))))))
            (VP (VBZ:[1263..1265] is)
              (VP (VBN:[1266..1275] inhibited)
                (NP-1 (-NONE-:[1275..1275] *))
                (PP (IN:[1276..1278] by)
                  (NP-LGS
                    (ADJP (RB:[1279..1284] quite) (JJ:[1285..1294] different))
                    (JJ:[1295..1307] inhalational)
                     (NNS:[1309..1320] anesthetics)))
                (PP (IN:[1321..1323] at)
                  (NP
                    (ADJP (RB:[1324..1334] clinically)
                          (JJ:[1335..1343] relevant))
                    (NNS:[1344..1358] concentrations)))))))))
    (.:[1358..1359] .)))

;section 10 Span:1363..1407
;PMID: 7885185 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1363..1367] PMID) (::[1367..1368] :) (CD:[1369..1376] 7885185)
        (NN:[1377..1378] -LSB-) (NNP:[1378..1384] PubMed) (::[1385..1386] -)
        (NN:[1387..1394] indexed) (IN:[1395..1398] for)
        (NNP:[1399..1406] MEDLINE) (-RRB-:[1406..1407] -RSB-)))
